Biogen Idec, Isis pen third antisense drug discovery deal this year
In their third deal this year, public biotechs Biogen Idec Inc. and Isis Pharmaceuticals Inc. have partnered to discover and develop antisense drug candidates against three undisclosed targets to treat neurological or neuromuscular disorders.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.